Representative Image
NEW DELHI: The Drug Controller General of India (DCGI) has approved India’s first indigenously vaccine candidate, COVAXIN, for clinical trials Phase 1 and 2 in infected people.
The vaccine was innovated by Bharat Biotech, in collaboration with Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV). The company has scheduled human trials for July 2020.
Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech, has said that the collaboration with NIV and ICMR was instrumental in the development of the vaccine.
The press release of the company said that the results from the pre-clinical studies have been promising and show extensive safety and effective immune response.
Along with the Bharat Biotech, five other Indian companies are working on development of a vaccine.
Representative Image NEW DELHI: The India Meteorological Department (IMD) has issued a warning regarding an…
Representative Image JAMMU and KASHMIR: The National Green Tribunal (NGT) has called upon the Central…
Representative Image NEW DELHI: The 19th edition of the United Nations Forum on Forests (UNFF…
Representative Image MUMBAI, Maharashtra: The Brihanmumbai Municipal Corporation (BMC) has published a list of 188…
Representative Image CHENNAI, Tamil Nadu: The Greater Chennai Municipal Corporation is mulling the plan to…
Representative Image TRICHIRAPALLI, Tamil Nadu: Faulty Streetlights on the newly built Kollidam Bridge in Trichy…